Clinical Trial: Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment

Brief Summary:

The Chronic Hypersensitivity Pneumonitis (HP), is an inflammatory disease who has an evolution to develop progressive interstitial fibrosis, who cause the death of the patient. Actually HP has been treated with Prednisone and occasionally with Azathioprine, but unfortunately the treatment with these drugs have not an effective result to treat the interstitial fibrosis.

Pirfenidone has been studied over the world for the treatment of Fibrotic diseases, with positive results, and due to the Pirfenidone mechanism of action has anti-inflammatory and anti-fibrotic properties, the investigators propose to evaluate the addition of Pirfenidone to the actual treatment with Prednisone and Azathioprine in the treatment of patients with Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis.

Detailed Summary:

The Chronic Hypersensitivity Pneumonitis (HP), is a complex syndrome due to a exaggerated immune response caused by inhalation of foreign substances, such as molds, dusts, and organic particles, causing alveoli inflammation and in the chronic forms the disease has high rate of mortality, due to the big number of patients who develop progressive interstitial fibrosis and eventually they curse with respiratory insufficiency who cause the death of the patient.

Pirfenidone has been studied over the world for the treatment of Idiophatic Pulmonary Fibrosis (IPF), disease who constitute the most aggressive of the fibrotic diseases of the lung. Additionally Pirfenidone has been showed potential results in the treatment of fibrotic diseases in other organs, as Liver, Kidney, Hearth, etc. Pirfenidone has been described as a modulator of the fibrotic process due to his action over TGF-beta and MMP´s and also has into-inflammatory actions acting over TNF-alfa and IL-1 and IL-6.

Actually HP has been treated with Prednisone and occasionally with Azathioprine, but a high number of patients will develop irreversibly to a interstitial fibrosis with pulmonary parenchyma destruction. Unfortunately the investigators have not an effective treatment for this cases. Due to the positive results obtained with Pirfenidone in the treatment of IPF and other kind of organ fibrosis, the investigators propose to evaluate the addition of Pirfenidone to the treatment with Prednisone and Azathioprine in the treatment of patients with Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis.

Sponsor: Grupo Medifarma, S. A. de C. V.

Current Primary Outcome: Forced Vital Capacity (FVC) [ Time Frame: 52 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

• High Resolution Tomography [ Time Frame: 52 weeks ]
  Evaluation of the inflammation and fibrosis grade with the Kazerooni scale
• 6 minutes walk distance test [ Time Frame: 52 weeks ]
  quantification of the walking distance at 6 minutes
• San George Qty Score, SOBQ and EQ5D Quality Scores [ Time Frame: 52 weeks ]
  As a composite outcome to evaluate the quality of life
• Pulmonary artery systolic pressure with echocardiogram [ Time Frame: 52 weeks ]
  measurement of pressure
• Oxygen desaturation in exercise [ Time Frame: 52 weeks ]
  Measurement of Oxygen

Original Secondary Outcome: Same as current

Information By: Grupo Medifarma, S. A. de C. V.

Dates:
Date Received: July 6, 2015
Date Started: July 2015
Date Completion: January 2017
Last Updated: July 13, 2015
Last Verified: July 2015